Presentation is loading. Please wait.

Presentation is loading. Please wait.

Identifying Antibodies The Antibody Panel CLS 422 Clinical Immunohematology I.

Similar presentations


Presentation on theme: "Identifying Antibodies The Antibody Panel CLS 422 Clinical Immunohematology I."— Presentation transcript:

1 Identifying Antibodies The Antibody Panel CLS 422 Clinical Immunohematology I

2 Objectives Discuss clinical situations when it is appropriate to perform antibody identification. Define a panel of cells. Explain how the following factors aid in the interpretation of antibody panels: a.Cross-out technique b.Variation in strengths of reaction c.Phases of reaction d.Autocontrol e.Red blood cell antigen typing

3 Objectives List testing that can be performed to confirm the identification of antibodies. Identify the antibodies present, when given panel results.

4 When is an antibody identification panel performed? When the antibody screen is positive.

5 When to perform test The panel red blood cells (RBCs) are tested against the patient’s serum or plasma in order to identify the unexpected antibody or antibodies present.

6 Identification Antibody screen – positive Run antibody panel to identify antibody (-ies). If original panel does not provide a clear-cut ID, test additional RBCs. Selected cells Alternate methods

7 Confirmation Rule of 3 and 3 Antigen type patient’s RBCs. Landsteiner’s Law!!!

8 The Panel Series of 8 to 20 Group O RBCs Various distribution of the most common RBC antigens Suspended in a preservative to protect antigen integrity for 2 -4 weeks Packaged with a lot-specific antigram

9 Antigram

10 Donor Cell number DCcEe CwCw Kk Kp a Kp b Js a Js b Fy a Fy b Jk a Jk b Le a Le b P1P1 MNSs Lu a Lu b Xg a RZR R1w R R2R r’r r’’r rrK rrFya Ror rr R2r R1R Patient Cells Panel Antigram

11 Auto Control Patient’s serum/plasma tested against a suspension of patient’s RBCs Optional Evaluate results in conjunction with patient history Autoantibody Newly forming alloantibody If patient has a positive DAT, auto control will be positive

12 Usually the same as was used for the antibody screen Must include incubation at 37 o C Must include an AHG phase with reagent containing anti-IgG Test Method

13 Interpreting Panel Results

14 Cell DCcEeCwCw KkKp a Kp b JsaJsa JsbJsb FyaFya FybFyb JkaJka JkbJkb LeaLea LebLeb P1P1 MNSs LuaLua Lu b XgaXga AHGAHG CC w++w Auto02+

15 Exclusion Begin with the RBCs that failed to react The antibody in the serum is not directed against the antigens on these RBCs, so we can eliminated these antibody specificities Look at alleles to avoid problems with dosage! Exclusion should be done using RBCs having homozygous antigen expression. Exceptions are low prevalence antigens

16 Cell DCcEeCwCw KkKp a Kp b JsaJsa JsbJsb FyaFya FybFyb JkaJka JkbJkb LeaLea LebLeb P1P1 MNSs LuaLua Lu b XgaXga AHGAHG CC w++w Auto02+ Exclusion

17 Inclusion Of the antibody specificities that have not been excluded, match the pattern of positive and negative reactions with the pattern of antigen positive and antigen negative cells. There must be an explanation for each positive reaction seen.

18 Cell DCcEeCwCw KkKp a Kp b JsaJsa JsbJsb FyaFya FybFyb JkaJka JkbJkb LeaLea LebLeb P1P1 MNSs LuaLua Lu b XgaXga AHGAHG CC w++w Auto02+ Inclusion

19 Other Points to Consider In what phase(s) of testing is the antibody reactive? May give clue as to antibody identity and clinical significance. Is the strength of reaction the same for each cell that reacts, or is there variation in strength? Dosage, antigen variability, or multiple antibodies. Is the antibody reacting only with “homozygous” cells of a certain specificity? Weak antibody showing dosage. Did the autologous control react? Autoantibody or newly forming alloantibody.

20 Probability Rule of 3 and 3 For each antibody specificity, are there 3 antigen positive cells that reacted and 3 antigen negative cells that did not react? May use screen cells in addition to panel cells to fill this rule Cells do not need to have homozygous antigen expression to fill this rule

21 Cell DCcEeCwCw KkKp a Kp b JsaJsa JsbJsb FyaFya FybFyb JkaJka JkbJkb LeaLea LebLeb P1P1 MNSs LuaLua Lu b XgaXga AHGAHG CC w++w Auto02+ The Rule of 3 and 3

22 Antigen Typing Confirms the antibody identification LANDSTEINER’S LAW Test patient’s RBCs (unknown antigen) against appropriate anti-sera (known antibody) Results should be negative Run positive and negative controls for anti-sera A positive DAT or recent transfusion may invalidate the typing results

23 Cell DCcEeCwCw KkKp a Kp b JsaJsa JsbJsb FyaFya FybFyb JkaJka JkbJkb LeaLea LebLeb P1P1 MNSs LuaLua Lu b XgaXga AHGAHG CC w++w Auto02+ Selecting Controls for Antigen Typing

24 Value of Patient History The following additional information may assist in determining the identity of the antibody: History of antibodies Transfusion, transplant, pregnancy (how many and how long ago) Medications Diagnosis Ethnicity

25 Reporting Panel results are reported as “anti-” and then the specificity Anti-K If specificity cannot be determined at this point, additional testing must be performed

26 The End


Download ppt "Identifying Antibodies The Antibody Panel CLS 422 Clinical Immunohematology I."

Similar presentations


Ads by Google